Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Kornmann

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen|September 18, 2009
[Quality criteria for treatment of colorectal cancer. From a surgeon's viewpoint]K H Link, M Kornmann, R Bittner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 31, 2013
Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP)H Fensterer, C Schade-Brittinger, H-H Müller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2022
Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer groupT Seufferlein, W Uhl, M Kornmann, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen|September 18, 2009
[Quality criteria for treatment of colorectal cancer. From a surgeon's viewpoint]K H Link, M Kornmann, R Bittner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 31, 2013
Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP)H Fensterer, C Schade-Brittinger, H-H Müller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2022
Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer groupT Seufferlein, W Uhl, M Kornmann, et al.
Pageof 6